Utpreksha Vaish

Dr. Utpreksha Vaish

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
UVUtpreksha Vaish
Utpreksha Vaish
TJTejeshwar Jain
Tejeshwar Jain
AAAbhi C. Are
Abhi C. Are
VDVikas Dudeja
Vikas Dudeja
Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related morbidity and mortality in the western world, with limited therapeutic strategies and dismal long-term survival. Cancer-associated fibroblasts (CAFs) are key components of the pancreatic tumor microenvironment, maintaining the extracellular matrix, while also being involved in intricate crosstalk with cancer cells and infiltrating immunocytes. Therefore, they are potential targets for developing therapeutic strategies against PDAC. However, recent studies have demonstrated significant heterogeneity in CAFs with respect to their origins, spatial distribution, and functional phenotypes within the PDAC tumor microenvironment. Therefore, it is imperative to understand and delineate this heterogeneity prior to targeting CAFs for PDAC therapy.

25 January 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
EBEjas Palathingal Bava
Ejas Palathingal Bava
JGJohn George
John George
MTMohammad Tarique
Mohammad Tarique
SISrikanth Iyer
Srikanth Iyer
PSPreeti Sahay
Preeti Sahay
VDVikas Dudeja
Vikas Dudeja
Despite decades of research, there is no specific therapy for acute pancreatitis (AP). In the current study, we have evaluated the efficacy of pirfenidone, an antiinflammatory and antifibrotic agent that is approved by the FDA for treatment of idiopathic pulmonary fibrosis (IPF), in ameliorating local and systemic injury in AP. Our results suggest that treatment with pirfenidone in therapeutic settings (e.g., after initiation of injury), even when administered at the peak of injury, reduces severity of local and systemic injury and inflammation in multiple models of AP. In vitro evaluation suggests that pirfenidone decreases cytokine release from acini and macrophages and disrupts acinar-macrophage crosstalk. Therapeutic pirfenidone treatment increases IL-10 secretion from macrophages preceding changes in histology and modulates the immune phenotype of inflammatory cells with decreased levels of inflammatory cytokines. Antibody-mediated IL-10 depletion, use of IL-10–KO mice, and macrophage depletion experiments confirmed the role of IL-10 and macrophages in its mechanism of action, as pirfenidone was unable to reduce severity of AP in these scenarios. Since pirfenidone is FDA approved for IPF, a trial evaluating the efficacy of pirfenidone in patients with moderate to severe AP can be initiated expeditiously.

12 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
UVUtpreksha Vaish
Utpreksha Vaish
AKAvinash A. Kumar
Avinash A. Kumar
SVSwati Varshney
Swati Varshney
SGShreya Ghosh
Shreya Ghosh
SSShantanu Sengupta
Shantanu Sengupta
RRRajni Rani
Rajni Rani
Translation of genes is regulated by many factors including microRNAs (miRNAs). miRNA profiling of lesional and non-lesional epidermal RNA from 18 vitiligo patients revealed significant upregulation of 29 miRNAs in the lesional epidermis, of which 6 miRNAs were transfected in normal human epidermal keratinocytes (NHEKs) to study their downstream effects using quantitative proteomics. Many proteins involved in oxidative stress, Vesicle trafficking, Cellular apoptosis, Mitochondrial proteins and Keratins were regulated after miRNA transfections in the keratinocytes. However, tyrosinase related protein-1 (TRP1/TYRP1), a melanogenesis protein, was consistently downregulated in NHEKs by all the six miRNAs tested, which was quite intriguing. TRP1 was also downregulated in lesional epidermis compared with non-lesional epidermis. Since melanocytes synthesize and transfer melanosomes to the surrounding keratinocytes, we hypothesized that downregulation of TRP1 in NHEKs may have a role in melanosome transfer, which was confirmed by our co-culture experiments. Downregulation of TRP1 in keratinocytes negatively affected the melanosome transfer from melanocytes to keratinocytes resulting in melanin accumulation which may be leading to melanin induced cytotoxicity in melanocytes. Regulation of key processes involved in aetiopathogenesis of vitiligo along with TRP1 suggests that miRNAs act in an integrated manner which may be detrimental for the loss of melanocytes in vitiligo.

31 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
HJHarrys Kishore Charles Jacob
Harrys Kishore Charles Jacob
John Lalith Charles RichardJohn Lalith Charles Richard
John Lalith Charles Richard
Rossana SignorelliRossana Signorelli
Rossana Signorelli
TKTyler Kashuv
Tyler Kashuv
SLshweta Lavania
shweta Lavania
ASAshok Saluja
Ashok Saluja
Tumor cells dissociate from the primary site and enter into systemic circulation (circulating tumor cells, CTCs) either alone or as tumor microemboli (clusters); the latter having an increased predisposition towards forming distal metastases than single CTCs. The formation of clusters is, in part, created by contacts between cell–cell junction proteins and/or cytokine receptor pairs with other cells such as neutrophils, platelets, fibroblasts, etc. In the present study, we provide evidence for an extravesicular (EV) mode of communication between pancreatic cancer CTCs and neutrophils. Our results suggest that the EV proteome of CTCs contain signaling proteins that can modulate degranulation and granule mobilization in neutrophils and, also, contain tissue plasminogen activator and other proteins that can regulate cluster formation. By exposing naïve neutrophils to EVs isolated from CTCs, we further show how these changes are modulated in a dynamic fashion indicating evidence for a deeper EV based remodulatory effect on companion cells in clusters.

1 May 2020 in Biologicals
Verified
Journal Article
Closed access
SCSubhash Chand
Subhash Chand
UVUtpreksha Vaish
Utpreksha Vaish
ASAnu Sharma
Anu Sharma
NMNripendra Nath Mishra
Nripendra Nath Mishra
JPJai Prakash Prasad
Jai Prakash Prasad
RMRichi V. Mahajan
Richi V. Mahajan

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
VSVrishketan Sethi
Vrishketan Sethi
JTJunyi Tao
Junyi Tao
SKSaba Kurtom
Saba Kurtom
UVUtpreksha Vaish
Utpreksha Vaish
Farrukh AfaqFarrukh Afaq
Farrukh Afaq
VDVikas Dudeja
Vikas Dudeja
Background: We have previously showed that gut microbiota-depleting oral antibiotics decrease tumor growth in C57BL/6J mice via the immune system (Sethi et al, Gastroenterology, 2018). The gut microbiota, however, includes thousands of species producing numerous metabolites. The search for individual bacterial species and metabolites that can promote cancer continues. Methods: We studied the effects of common microbiota modulation techniques in C57BL/6 mice procured from various commercial vendors and injected subcutaneously with cancer cells. 16S rRNA gene sequencing and metabolomics analyses were used to identify the putative cancer-promoting species and metabolites. Results: Mice procured from The Jackson Laboratory (JAX mice) form larger tumors at baseline compared to mice procured from the Charles River Laboratories (CR mice). JAX mice have tumor promoting microbiota that can be targeted by oral antibiotics unlike CR mice. This tumor-promoting microbiota gets transferred from JAX to CR mice via cohousing or fecal microbiota transplant. In a preclinical trial, oral vancomycin slowed the growth of cancer in avatar mice gavaged with stools of some pancreatic cancer patients but not of others. Statistical analyses reveal that the gut of JAX mice hosts a common human gram-positive gut commensal Ruminococcus gnavus that is associated with increased cancer growth in those mice. Monocolonization of germ-free mice with R gnavus directly increases tumor growth. Similarly, feeding R gnavus, but not a control bacterial species, brings the baseline tumor kinetics of CR mice up to that of JAX mice. Our experiments reveal that R gnavus needs sufficient dietary tryptophan (Trp) to promote tumor growth and in turn, catabolizes Trp into various metabolites including the Aryl Hydrocarbon Receptor (AHR) ligand Tryptamine, which we find, is also tumor-promoting per se. The tumor-modulating effects of oral vancomycin, tryptophan catabolites and R gnavus are abolished when murine AHR is stimulated by an exogenous ligand or when it is knocked out. Finally, we find that Ly6G+ cells are essential in effecting these bacteria-cancer interactions. Conclusions: We present initial evidence on how a common gut commensal hijacks an essential dietary amino acid to promote cancer via the AHR. We also demonstrate the essential but underappreciated role that the source of animal procurement plays in studies involving cancer models. Citation Format: Vrishketan Sethi, Junyi Tao, Saba Kurtom, Utpreksha Vaish, Farrukh Afaq, Shuan Zao, Xian Luo, Tejeshwar Jain, Prateek Sharma, Ejas Bava, Sundaram Ramakrishnan, Liang Li, Ashok Saluja, Vikas Dudeja. A common gut commensal utilizes tryptophan to promote cancer via the aryl hydrocarbon receptor [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3046.